Literature DB >> 26136932

Effect of Shenkang granules on the progression of chronic renal failure in 5/6 nephrectomized rats.

Y U Zhang1, Nan Zhou1, Hongying Wang1, Sicen Wang1, Jianyu He1.   

Abstract

Shenkang granules (SKGs) are a Chinese herbal medicinal formula, consisting of rhubarb (Rheum palmatum L.), Salvia miltiorrhiza, milkvetch root [Astragalus membranaceus (Fisch.) Bunge] and safflower (Carthamus tinctorius L.). The aim of the present study was to investigate the effect of SKG on chronic renal failure (CRF) in 5/6 nephrectomized (5/6 Nx) rats. The rats were randomly divided into seven groups (n=10 per group) as follows: (i) 5/6 Nx (model group; 2.25 ml/kg/day normal saline); (ii) SKGL (low dose; 5/6 Nx treated with 2 g crude drug/kg/day SKG); (iii) SKGM (moderate dose; 5/6 Nx treated with 4 g crude drug/kg/day SKG); (iv) SKGH (high dose; 5/6 Nx treated with 8 g crude drug/kg/day SKG); (v) benazepril treatment group (5/6 Nx treated with 5 mg/kg/day benazepril); (vi) Shenkang injection (SKI) group (5/6 Nx with 13.3 ml/kg/day SKI); and (vii) sham-operated group (2.25 ml/kg/day normal saline). After 30 days, the levels of microalbumin, total protein, serum creatinine, blood urea nitrogen and serum lipid were found to be significantly decreased in the SKGL and SKGM rats, showing histological improvement compared with the untreated 5/6 Nx rats, as determined by hematoxylin and eosin, and Masson's trichrome staining. In addition, SKG was found to significantly improve the levels of glutathione peroxidase and reduce the damage caused by free radicals to the kidney tissues. Furthermore, SKG prevented the accumulation of extracellular matrix by decreasing the expression of collagen I and III and inhibiting the expression of matrix metalloproteinases-2 and -9 in the renal tissue, as determined by western blot analysis. SKG was also shown to decrease the concentrations of serum transforming growth factor-β1, as determined by ELISA, and kidney angiotensin II, as determined using a radioimmunoassay kit. In conclusion, SKG was demonstrated to ameliorate renal injury in a 5/6 Nx rat model of CRF. Thus, SKG may exert a good therapeutic effect on CRF.

Entities:  

Keywords:  Shenkang granules; angiotensin II; chronic renal failure; proteinuria; transforming growth factor-β1

Year:  2015        PMID: 26136932      PMCID: PMC4473336          DOI: 10.3892/etm.2015.2383

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  43 in total

Review 1.  Angiotensin II, TGF-beta and renal fibrosis.

Authors:  J Gaedeke; H Peters; N A Noble; W A Border
Journal:  Contrib Nephrol       Date:  2001       Impact factor: 1.580

2.  Peripheral blood level alterations of MMP-2 and MMP-9 in patients with chronic kidney disease on conservative treatment and on hemodialysis.

Authors:  Krystyna Pawlak; Michal Mysliwiec; Dariusz Pawlak
Journal:  Clin Biochem       Date:  2011-04-16       Impact factor: 3.281

3.  Antifibrotic effect of tamoxifen in a model of progressive renal disease.

Authors:  Humberto Dellê; José Roberto C Rocha; Rita C Cavaglieri; José Mauro Vieira; Denise M A C Malheiros; Irene L Noronha
Journal:  J Am Soc Nephrol       Date:  2011-11-03       Impact factor: 10.121

4.  Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction.

Authors:  Christine A Houlihan; Aysel Akdeniz; Con Tsalamandris; Mark E Cooper; George Jerums; Richard E Gilbert
Journal:  Diabetes Care       Date:  2002-06       Impact factor: 19.112

5.  Acute unilateral ischemic renal injury induces progressive renal inflammation, lipid accumulation, histone modification, and "end-stage" kidney disease.

Authors:  Richard A Zager; Ali C M Johnson; Kirsten Becker
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-14

6.  Curcumin reverses glomerular hemodynamic alterations and oxidant stress in 5/6 nephrectomized rats.

Authors:  Edilia Tapia; Zyanya Lucía Zatarain-Barrón; Rogelio Hernández-Pando; Guillermo Zarco-Márquez; Eduardo Molina-Jijón; Magdalena Cristóbal-García; José Santamaría; José Pedraza-Chaverri
Journal:  Phytomedicine       Date:  2012-12-25       Impact factor: 5.340

7.  [Contrast study on effect of shenkang injection and benazepril on human glomerular mesangial extracellular matrix].

Authors:  L Guo; Y Liu; W Mao
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2000-01

8.  X-linked Alport syndrome in Hellenic families: phenotypic heterogeneity and mutations near interruptions of the collagen domain in COL4A5.

Authors:  P Demosthenous; K Voskarides; K Stylianou; M Hadjigavriel; M Arsali; C Patsias; E Georgaki; P Zirogiannis; C Stavrou; E Daphnis; A Pierides; C Deltas
Journal:  Clin Genet       Date:  2011-03-13       Impact factor: 4.438

9.  Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats.

Authors:  Deng-Yuan Jian; Yu-Wen Chao; Ching-Heng Ting; Seng-Wong Huang; Chao-Fu Chang; Chi-Chang Juan; Jinn-Yang Chen
Journal:  Eur J Pharmacol       Date:  2013-03-23       Impact factor: 4.432

Review 10.  Anemia management and the delay of chronic renal failure progression.

Authors:  Jerome Rossert; Bruno Fouqueray; Jean Jacques Boffa
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

View more
  7 in total

1.  ShenKang Injection Attenuates Renal Fibrosis by Inhibiting EMT and Regulating the Wnt/β-Catenin Pathway.

Authors:  Hui-Ting Wei; Yuan Xu; Xiao-Yang Tan; Hao-Yue Jing; Yue-Rong Ma
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-28       Impact factor: 2.650

2.  Pharmacokinetics and Metabolism Research of Shenkang Injection in Rats Based on UHPLC-MS/MS and UHPLC-Q-Orbitrap HRMS.

Authors:  Xiaofang Jiang; Lin Zhou; Lihua Zuo; Xiaohui Wang; Yingying Shi; Xiangyu Du; Jun Zhang; Liwei Liu; Zhuolun Li; Lianping Xue; Xin Liu; Zhi Sun
Journal:  Drug Des Devel Ther       Date:  2020-05-13       Impact factor: 4.162

3.  Shen-Kang protects against tacrolimus-induced renal injury.

Authors:  Long Ye Zhang; Jian Jin; Kang Luo; Shang Guo Piao; Hai Lan Zheng; Ji Zhe Jin; Sun Woo Lim; Bum Soon Choi; Chul Woo Yang; Can Li
Journal:  Korean J Intern Med       Date:  2018-02-12       Impact factor: 2.884

4.  Effect of Shenkang on renal fibrosis and activation of renal interstitial fibroblasts through the JAK2/STAT3 pathway.

Authors:  Tianyu Qin; You Wu; Tonghua Liu; Lili Wu
Journal:  BMC Complement Med Ther       Date:  2021-01-06

Review 5.  Promoting Plant-Based Therapies for Chronic Kidney Disease.

Authors:  Muhammad Ali Khan; Andrew J Kassianos; Wendy E Hoy; Ahm Khurshid Alam; Helen G Healy; Glenda C Gobe
Journal:  J Evid Based Integr Med       Date:  2022 Jan-Dec

6.  Astragalus polysaccharide, a component of traditional Chinese medicine, inhibits muscle cell atrophy (cachexia) in an in vivo and in vitro rat model of chronic renal failure by activating the ubiquitin-proteasome pathway.

Authors:  Zhenbo Geng; Lianbo Wei; Chunhua Zhang; Xiaohua Yan
Journal:  Exp Ther Med       Date:  2017-05-22       Impact factor: 2.447

7.  Efficacy and safety of Shenkang injection in the treatment of chronic renal failure: A protocol of a randomized controlled trial.

Authors:  JuXiang Mei; LingLing Yang; Deqin Wang; HaiXia Wang
Journal:  Medicine (Baltimore)       Date:  2021-12-03       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.